Astrana Health, Inc.
A physician-led healthcare technology company in Alhambra, California, Astrana Health supports doctors and independent medical groups by providing the management services, data analytics, and care-coordination tools they need under value-based care, where providers are paid for patient outcomes rather than a flat fee per visit. Founded in the early 1990s by a team of physicians, the company rebranded from Apollo Medical Holdings in 2024. Its name, drawn from roots meaning "a collection of stars," honors the founding doctors and its network of providers working together like a constellation.
Item 4 is hereby amended to add the following: On January 15, 2025, the Reporting Person declared a dividend on the Reporting Person's common stock, payable by the pro rata distribution, for no consideration, of an aggregate of 699,896 shares of the Issuer's Common Stock to the Reporting Person's stockholders, including 17,839 shares in the aggregate held for the benefit of disqualified shareholders of the Reporting Person. The shares of Common Stock were distributed on February 15, 2025. The Reporting Person acquired the Common Stock reported in this Statement for investment purposes. The Reporting Person may in the future acquire additional shares of Common Stock or dispose of some or all of the shares of Common Stock beneficially owned by it in open-market transactions or privately negotiated transactions, on such terms and at such times as it may deem advisable. The Reporting Person may engage in hedging or similar transactions with respect to the shares of Common Stock, on such terms and at such times as the Reporting Person may deem advisable, subject to applicable law. The Reporting Person does not have any present plan or proposal that would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or as may be proposed by officers or directors of the Reporting Person in their capacity as an officer and/or director of the Issuer or by the Board of Directors of the Issuer with their participation. The Reporting Person reserves the right in the future to formulate any such plans or proposals, and to take any actions with respect to its investments in the Issuer, including any or all of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Vanguard Portfolio Management | 13GPassive | 5.34% | 2.65M | Jul 31, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| BlackRock, Inc. | 13G/APassive | 12.4% | 6.23M | Apr 17, 2025 |
| Allied Physicians of California, a Professional Medical Corporation | 13D/AActivist | 11% | 6.13M | Feb 18, 2025 |
Item 4 is hereby amended to add the following: On January 15, 2025, the Reporting Person declared a dividend on the Reporting Person's common stock, payable by the pro rata distribution, for no consideration, of an aggregate of 699,896 shares of the Issuer's Common Stock to the Reporting Person's stockholders, including 17,839 shares in the aggregate held for the benefit of disqualified shareholders of the Reporting Person. The shares of Common Stock were distributed on February 15, 2025. The Reporting Person acquired the Common Stock reported in this Statement for investment purposes. The Reporting Person may in the future acquire additional shares of Common Stock or dispose of some or all of the shares of Common Stock beneficially owned by it in open-market transactions or privately negotiated transactions, on such terms and at such times as it may deem advisable. The Reporting Person may engage in hedging or similar transactions with respect to the shares of Common Stock, on such terms and at such times as the Reporting Person may deem advisable, subject to applicable law. The Reporting Person does not have any present plan or proposal that would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or as may be proposed by officers or directors of the Reporting Person in their capacity as an officer and/or director of the Issuer or by the Board of Directors of the Issuer with their participation. The Reporting Person reserves the right in the future to formulate any such plans or proposals, and to take any actions with respect to its investments in the Issuer, including any or all of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D | ||||